TickerTalks
Browse all tickers →
TickerTalks›$MRK
MRMRK

Merck & Co., Inc.

$MRK·$318B·Drug Manufacturers - General·Healthcare
$147.76-0.4%YTD+21.3%1Y+72.9%
Mentions · last 7 days
2026-08-22: 47 posts1,753+3%
Price updated 7h ago·X counts updated 9d ago
MRMRK
$MRKMerck & Co., Inc.
$147.76-0.40%1.8k posts+3%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $MRK, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Proven numbersAcceleratingAI verdict · as of 2026-08-30

The move is getting stronger, with heavier trading behind it.

A century of failed cancer vaccines just ended with a Merck-partnered Phase 3 win — that's the tape.

Merck is a large-cap pharma with a maturing Keytruda oncology franchise, and its co-developed mRNA-4157 melanoma vaccine with Moderna just cleared Phase 3 — the first mRNA cancer treatment to do so. The stock hit a new 52-week high on the readout and the crowd is treating it as durable.

  • The base business is a large, real earner: quarterly revenue ran $15.8B / $17.2B / $16.3B / $16.3B across the last four quarters at a 76% blended gross margin, and analysts model $66.8B of full-year revenue — the melanoma readout matters at the pipeline-value level, but the printing press behind it means the story doesn't rely on it.
  • The Q1 EPS optic is misleading: Q1 printed -$1.72 on charges tied to a business acquisition, while Q2 through Q4 delivered $1.76 / $2.32 / $1.20 — the underlying earnings power is what analysts pencil in at ~$2.76 for the full year, which is why the stock is at 21% YTD and 78% TTM at $148.
  • The cancer-vaccine catalyst is genuinely new commercial optionality: mRNA-4157 opens Merck's oncology bench beyond Keytruda for the first time in years, and a working mRNA cancer platform reshapes how the sell-side prices the durability of Keytruda's cliff — a set of numbers that were priced as a fade can now be priced as an extended runway.

An Oct 29 print that carries the operational momentum and puts the melanoma vaccine on a clear commercial timeline extends the rally into 12x-forward territory that's still cheap for a pharma this diversified; the risk is a subsequent Phase 3 miss in a follow-on tumor indication or a US pricing headline that reprices the whole big-pharma group.

Agrees with X sentimentX's bullish framing is well-anchored — the +12.6% move on the mRNA-4157 readout is a genuine Phase 3 event, not a chart move, and the healthcare-sector-lift framing is reasonable given how much oncology optionality has been priced out over the last two years.

What to watch: The Oct 29 print — Keytruda growth curve, any commercial timeline color on the melanoma vaccine, and pipeline update on follow-on tumor indications. A subsequent Phase 3 miss anywhere in the mRNA-4157 platform reverses the rerating.

On the calendar: 2026-10-29 — Q3 earnings

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bullish sentiment41 posts analyzed · as of 2026-08-31

Merck sits at all-time highs and the tape is celebratory, powered by the Moderna-partnered intismeran Phase 3 melanoma win, which a TD Cowen KOL calls "practice-changing" if RFS HR stays below 0.70. Posters flag it as SCHD's new #1 holding and a dividend king, with Wolfe modeling $9.2B peak sales across four indications. Longer-horizon skeptics flag the pharma patent cliff through 2033 as an overhang.

Read the AI verdict + X sentiment for $MRK

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Makes Keytruda cancer immunotherapy, Gardasil HPV vaccine, and animal health products with a strong oncology pipeline.

Industry overviewAI analysisGenerated by AI from underlying data

Where Drug Manufacturers - General sits in its cycle right now — and what that implies for $MRK.

Drug Manufacturers - General · Healthcare

GLP-1 obesity/diabetes franchise expansion is the sector's defining growth dynamic; LLY and NVO are capturing most of the incremental spend while the industry realigns R&D pipelines. Patent cliff management — biosimilar exposure and pipeline offset — is the critical risk for legacy pharma names.

What this means for $MRK

Partial — fee-based midstream revenue has limited direct commodity price exposure but volume ties to upstream production activity.

Top industry ETF

$IHEiShares U.S. Pharmaceuticals ETF
+19.1%YTD
+45.2%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
33.4How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
13.3%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
27.6%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
4.7%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
4.5Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
17.9%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
75.9%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
1.1Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 4, 2026$-0.13$-0.27+51.9%
Q1 2026Apr 30, 2026$-1.28$-1.47+12.9%
Q4 2025Feb 3, 2026$2.04$2.01+1.5%
Q3 2025Oct 30, 2025$2.58$2.36+9.3%
Next earningsThu, Oct 29·consensus EPS $2.22

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$16.3B+4.3%81.9%-11.6%$-1.72$2.9B
Q4 FY25$16.3B+4.5%70.5%37.7%$1.20$1.8B
Q3 FY25$17.2B+3.2%75.6%43.4%$2.32$6.8B
Q2 FY25$15.8B-1.9%75.7%40.2%$1.76$2.5B

Forward consensus

5-year forecast · up to 17 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$66.8B$66.5B – $67.7B$2.76$2.63 – $2.8915
FY27$70.2B$69.5B – $71.5B$9.61$9.18 – $9.9514
FY28$74.3B$70.9B – $78.5B$10.59$9.46 – $11.9117
FY29$74.3B$72.8B – $76.3B$10.17$9.90 – $10.5214
FY30$74.0B$72.6B – $76.0B$9.81$9.56 – $10.158

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.1.1×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.88%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+11.8%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+26.0%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMega float · 2.5B shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.4% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.215-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellAug 13Chirfi GuindoEVP, Access, Policy & Comms10.0K sh$1.4MSellAug 12Jennifer ZacharyEVP, General Counsel80.3K sh$10.7MSellAug 12Richard R. DelucaEVP&Pres, Merck Animal Heallth11.7K sh$1.5MSellAug 11Richard R. DelucaEVP&Pres, Merck Animal Heallth12.8K sh$1.7MSellAug 10Richard R. DelucaEVP&Pres, Merck Animal Heallth20.8K sh$2.7MSellAug 6Richard R. DelucaEVP&Pres, Merck Animal Heallth6.0K sh$789KSellAug 6Chirfi GuindoEVP, Access, Policy & Comms15.0K sh$2.0MSellAug 5David R. MaraldoEVP & Pres. MMD2.7K sh$346KSellAug 5Williams David MichaelEVP,Chief Info&Digital Officer34.7K sh$4.5M
+ 42 other (27 awards · 9 exempts · 6 inkinds) in window

See when $MRK insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KShareholder voteMay 288-K — Item 5.07: Shareholder vote
AI summary

Merck & Co., Inc. held its Annual Meeting of Shareholders on May 26, 2026, at which shareholders voted on director elections, executive compensation (say-on-pay), and other proposals as described in the proxy statement. Final voting results for each nominee and proposal are provided in the 8-K. This is a routine annual meeting governance disclosure with no material corporate actions taken.

424B5Prospectus supplement (offering)May 20424B5
AI summary

Merck & Co., Inc. (MRK) priced a $6 billion multi-tranche senior notes offering on May 20, 2026, comprising: $500M Floating Rate Notes due 2028, $1B 4.300% Notes due 2028, $500M 4.650% Notes due 2031, $1B 4.950% Notes due 2033, $1.5B 5.200% Notes due 2036, $500M 5.750% Notes due 2046, and $1B 5.850% Notes due 2056. This is a large investment-grade debt capital markets transaction for Merck; proceeds are likely earmarked for general corporate purposes, which may include funding the company's acquisition strategy or refinancing maturing debt.

424B5Prospectus supplement (offering)May 18424B5
AI summary

Merck and Co., Inc. (MRK) filed a preliminary 424B5 prospectus supplement on May 18, 2026 under Registration No. 333-278066 for a multi-tranche debt offering comprising Floating Rate Notes and multiple fixed-rate note series at various maturities. All specific dollar amounts and interest rates are left blank in this pre-pricing document. This is a debt capital markets transaction (not equity dilution) with proceeds intended for general corporate purposes consistent with Merck's ongoing capital needs.

3/ANew insider — initial holdingsMay 53/A
AI summary

Form filed by More than One Reporting Person Table I - Non-De filed a Form 3/A (amended) for MRK on 2026-05-05, initiating required Section 16 reporting. Role: of Reporting Person. Beneficial ownership covers 2026 shares. Form 3 is a mandatory administrative filing upon first becoming an insider or 10%+ holder; it does not reflect a purchase or sale event.

3New insider — initial holdingsMay 43
AI summary

Form filed by More than One Reporting Person Table I - Non-De filed a Form 3 (initial ownership statement) for MRK on 2026-05-04, initiating required Section 16 reporting. Role: of Reporting Person. Beneficial ownership covers 2026 shares. Form 3 is a mandatory administrative filing upon first becoming an insider or 10%+ holder; it does not reflect a purchase or sale event.

3New insider — initial holdingsMar 123
+ 19 other (3 11-Ks · 2 10-Qs · 2 13Fs · 2 earnings 8-Ks) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Warren Buffett Thinks Investors Are "Gambling" Right Now. Here are 2 Stocks That Should Be Safe Bets.fool.com·4d agoSuccess after a century of failures: Inside Moderna and Merck's cancer vaccine breakthroughreuters.com·4d agoMerck Stock Hits New 52-Week High: What's Driving the Rally?zacks.com·6d agoFidelity vs VanEck Healthcare ETFs: Broad Exposure or Pharma Focusfool.com·6d agoBeverly Hills Private Wealth LLC Cuts Stock Holdings in Merck & Co., Inc. $MRKdefenseworld.net·6d ago

In themes

Explore the broader themes this ticker is being talked about under.

GLP-1 & Weight Loss

More in Drug Manufacturers - General

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$LLY$PFE$NVO$JNJ$GILD$ABBV$AMGN$AZN
Voices on X · top 15 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport